BGB A317

Drug Profile

BGB A317

Alternative Names: BGBA317

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Solid tumours

Most Recent Events

  • 30 Dec 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease) in China (Parenteral)
  • 11 Nov 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in New Zealand (Parenteral) after November 2016
  • 11 Nov 2016 Safety and efficacy data from a phase I trial in Solid tumours presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top